MA31924B1 - Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) - Google Patents
Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)Info
- Publication number
- MA31924B1 MA31924B1 MA32926A MA32926A MA31924B1 MA 31924 B1 MA31924 B1 MA 31924B1 MA 32926 A MA32926 A MA 32926A MA 32926 A MA32926 A MA 32926A MA 31924 B1 MA31924 B1 MA 31924B1
- Authority
- MA
- Morocco
- Prior art keywords
- sphingosine
- phosphate
- active
- alkyl group
- hydrogen atom
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title abstract 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne des composés à base d'oxadiazole de formule (i) actifs sur la sphingosine-1-phosphate (s1p), en particulier utiles pour traiter le lupus érythémateux. A est un groupe phényle ou un cycle hétéroaryle à 5 ou 6 chaînons; r1 représente jusqu'à deux substituants indépendamment choisis parmi un atome d'halogène, un groupe alcoxy en c1-3, fluoroalkyle en c1-3, cyano, phényle éventuellement substitué, un groupe fluoroalkoxy en c1-3, alkyle en c1-6 et cycloalkyle en c3-6; r2 est un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en c1-4; b est un cycle saturé à 7 chaînons choisi parmi : formules (a) (b) (c); r3 est un atome d'hydrogène ou (ch2)1-4mco2h; r4 est un atome d'hydrogène ou groupe alkyle en c1-3 éventuellement interrompu par un atome d'oxygène
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0725120A GB0725120D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| GB0821918A GB0821918D0 (en) | 2008-12-01 | 2008-12-01 | Compounds |
| PCT/EP2008/067965 WO2009080725A1 (fr) | 2007-12-21 | 2008-12-19 | Dérivés d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31924B1 true MA31924B1 (fr) | 2010-12-01 |
Family
ID=40342566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32926A MA31924B1 (fr) | 2007-12-21 | 2010-06-16 | Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8222245B2 (fr) |
| EP (1) | EP2222669B1 (fr) |
| JP (1) | JP2011506569A (fr) |
| KR (1) | KR20100108566A (fr) |
| CN (1) | CN101945863B (fr) |
| AR (1) | AR069916A1 (fr) |
| AU (1) | AU2008339988B2 (fr) |
| BR (1) | BRPI0820131A2 (fr) |
| CA (1) | CA2710130A1 (fr) |
| CO (1) | CO6290646A2 (fr) |
| CR (1) | CR11579A (fr) |
| DK (1) | DK2222669T3 (fr) |
| DO (1) | DOP2010000194A (fr) |
| EA (1) | EA017691B1 (fr) |
| ES (1) | ES2434730T3 (fr) |
| HR (1) | HRP20130957T1 (fr) |
| IL (1) | IL206235A0 (fr) |
| MA (1) | MA31924B1 (fr) |
| NZ (1) | NZ585996A (fr) |
| PE (1) | PE20091339A1 (fr) |
| PL (1) | PL2222669T3 (fr) |
| PT (1) | PT2222669E (fr) |
| RS (1) | RS53038B (fr) |
| SI (1) | SI2222669T1 (fr) |
| TW (1) | TWI415847B (fr) |
| UY (1) | UY31570A1 (fr) |
| WO (1) | WO2009080725A1 (fr) |
| ZA (1) | ZA201003963B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| MY160526A (en) | 2008-12-22 | 2017-03-15 | Merck Patent Gmbh | Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011028927A1 (fr) * | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Antagonistes sélectifs des récepteurs de sphingosine-1-phosphate |
| CA2834164A1 (fr) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Benzoxazinones fusionnees comme modulateurs de canal ionique |
| CN102250035A (zh) * | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途 |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
| RU2543485C2 (ru) * | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| CN104844535A (zh) * | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
| TWI689487B (zh) | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| JP6590927B2 (ja) * | 2014-11-14 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド |
| ES2732437T3 (es) * | 2014-12-01 | 2019-11-22 | Idorsia Pharmaceuticals Ltd | Moduladores del receptor de CXCR7 |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| CN117479934A (zh) * | 2021-02-10 | 2024-01-30 | 西奈山伊坎医学院 | 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂 |
| US20250263405A1 (en) * | 2021-11-04 | 2025-08-21 | Valo Health, Inc. | Histone deacetylase 6 inhibitor compounds and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP4272423B2 (ja) | 2000-11-14 | 2009-06-03 | スミスクライン ビーチャム ピー エル シー | ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤） |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| ES2558761T3 (es) | 2003-05-19 | 2016-02-08 | Novartis Ag | Compuestos y composiciones inmunosupresores |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| EP1760071A4 (fr) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | Composé ayant une activité de liaison aux récepteurs s1p et utilisation de celui-ci |
| GB0414795D0 (en) | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Compounds |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| EP2592066B1 (fr) * | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Dérivé d'acide aminocarboxylique et son utilisation médicale |
| US7723378B2 (en) * | 2005-03-23 | 2010-05-25 | Actelion Pharmaceuticals Ltd. | Hydrogenated benzo (C) thiophene derivatives as immunomodulators |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| WO2007024922A1 (fr) | 2005-08-23 | 2007-03-01 | Irm Llc | Composes immunosuppresseurs et compositions associees |
| JP2009517351A (ja) | 2005-11-24 | 2009-04-30 | グラクソ グループ リミテッド | 化学物質 |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| AU2007323557A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2008
- 2008-12-18 PE PE2008002122A patent/PE20091339A1/es not_active Application Discontinuation
- 2008-12-19 EA EA201070782A patent/EA017691B1/ru not_active IP Right Cessation
- 2008-12-19 EP EP08864021.4A patent/EP2222669B1/fr active Active
- 2008-12-19 AR ARP080105590A patent/AR069916A1/es not_active Application Discontinuation
- 2008-12-19 UY UY31570A patent/UY31570A1/es unknown
- 2008-12-19 HR HRP20130957AT patent/HRP20130957T1/hr unknown
- 2008-12-19 CA CA2710130A patent/CA2710130A1/fr not_active Abandoned
- 2008-12-19 CN CN2008801273456A patent/CN101945863B/zh not_active Expired - Fee Related
- 2008-12-19 TW TW097149553A patent/TWI415847B/zh not_active IP Right Cessation
- 2008-12-19 KR KR1020107016167A patent/KR20100108566A/ko not_active Ceased
- 2008-12-19 AU AU2008339988A patent/AU2008339988B2/en not_active Expired - Fee Related
- 2008-12-19 US US12/747,205 patent/US8222245B2/en not_active Expired - Fee Related
- 2008-12-19 ES ES08864021T patent/ES2434730T3/es active Active
- 2008-12-19 BR BRPI0820131 patent/BRPI0820131A2/pt not_active IP Right Cessation
- 2008-12-19 JP JP2010538741A patent/JP2011506569A/ja active Pending
- 2008-12-19 PT PT88640214T patent/PT2222669E/pt unknown
- 2008-12-19 RS RS20130479A patent/RS53038B/sr unknown
- 2008-12-19 WO PCT/EP2008/067965 patent/WO2009080725A1/fr not_active Ceased
- 2008-12-19 SI SI200831050T patent/SI2222669T1/sl unknown
- 2008-12-19 DK DK08864021.4T patent/DK2222669T3/da active
- 2008-12-19 PL PL08864021T patent/PL2222669T3/pl unknown
- 2008-12-19 NZ NZ585996A patent/NZ585996A/en not_active IP Right Cessation
-
2009
- 2009-01-28 US US12/360,886 patent/US20100174065A1/en not_active Abandoned
-
2010
- 2010-06-03 ZA ZA2010/03963A patent/ZA201003963B/en unknown
- 2010-06-07 IL IL206235A patent/IL206235A0/en unknown
- 2010-06-16 MA MA32926A patent/MA31924B1/fr unknown
- 2010-06-21 DO DO2010000194A patent/DOP2010000194A/es unknown
- 2010-06-21 CO CO10074455A patent/CO6290646A2/es active IP Right Grant
- 2010-07-21 CR CR11579A patent/CR11579A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31924B1 (fr) | Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) | |
| DE60137405D1 (de) | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente | |
| ATE293101T1 (de) | Piperidine zur verwendung als orexin rezeptor antagonisten | |
| HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
| DE69503803D1 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| RU2012130959A (ru) | Фенольные производные и их фармацевтическое или косметическое применение | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| MY146646A (en) | 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis | |
| CA2324418A1 (fr) | Nouveaux composes opiaces et leurs procedes de preparation et d'utilisation | |
| RU2009133453A (ru) | Фторсодержащее пиразолкарбонитрильное производное и способ его получения и фторсодержащее производное пиразолкарбоновой кислоты, полученное с применением фторсодержащего пиразолкарбонитрильного производного и способ его получения | |
| RU2010101004A (ru) | Новые микробиоциды | |
| MA32642B1 (fr) | Amides utiles en therapie | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA31922B1 (fr) | Dérivés d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p) | |
| ATE252561T1 (de) | Chinolinderivate als mek enzym-inhibitoren | |
| MA35113B1 (fr) | 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5 | |
| MA38885B1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
| MA29343B1 (fr) | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine | |
| ATE550332T1 (de) | 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors | |
| BR0308759A (pt) | Derivados de fenil amidas siliconadas utilizáveis como microbiocida | |
| PH12021551133A1 (en) | N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | |
| SG165361A1 (en) | Antituberculous composition comprising oxazole compounds | |
| DK1341794T3 (da) | Fungicide 6-(2-trifluormethyl-phenyl)-triazolopyrimidiner |